SBRT Misses the Mark in Prostate Cancer Trial
(MedPage Today) -- Stereotactic body radiotherapy (SBRT) for localized prostate cancer did not improve urinary irritation or disease-free-survival (DFS) compared with hypofractionated intensity-modulated radiotherapy (IMRT), a large randomized...
A recent randomized trial found stereotactic body radiotherapy (SBRT) for localized prostate cancer did not outperform hypofractionated intensity-modulated radiotherapy (IMRT) in reducing urinary irritation or improving disease-free-survival. After 3.2 years, urinary-irritative symptoms were equally common in both groups, at 35.4% and 33.7% respectively.
However, IMRT provided a modest benefit in overall survival after three years, with 92.1% versus 88.6%. The rate of prostate specific antigen failure did not differ between the two treatments. The findings suggest SBRT may offer certain advantages, such as convenience and lower cost, while IMRT continues to show a slight edge in survival rates.
The results underscore the importance of considering multiple factors beyond radiation dose in optimizing prostate cancer treatment.
Written by urgent.news from MedPage Today's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
